Oncopharmpod
It's All Immunotherapy Nowadays
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:17:23
- Mas informaciones
Informações:
Sinopsis
Durvalumab's FDA-approval for NSCLC and the supporting PACIFIC study are discussed, then the ASCO Immunotherapy Toxicity Management Guidelines (7:45) are reviewed. Also, a plug for patient support groups.
